Nektar again looks to bempeg to sweeten its valuation
The depressed company’s bempegaldesleukin, which underwhelmed in melanoma, now faces two key near-term clinical data readouts.
No land grab for Gemini in geographic atrophy
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
The window of opportunity opens wider for Ascendis
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
Glaxo dips a lonely big pharma toe into the coeliac space
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
Success still eludes pancreatic cancer pipeline
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Ascendis shoots higher on pivotal win
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
German Merck and Glaxo clasp hands in oncology
The €300m deal is in part a high-stakes bid to take on Merck & Co's Keytruda in lung cancer.